688575.SS SHH
Shenzhen YHLO Biotech Co., Ltd.
1W: +0.9%
1M: +2.5%
3M: +14.8%
YTD: -22.9%
1Y: -33.1%
3Y: -43.5%
5Y: -65.2%
¥10.53 ($1.57)
+0.23 (+2.23%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$1.8B
-10.1% ▼
5Y CAGR: +12.6%
Gross Profit
$1.8B
+40.1% ▲
5Y CAGR: +26.2%
Operating Income
$110M
-65.0% ▼
5Y CAGR: -14.8%
Net Income
$24M
-92.0% ▼
5Y CAGR: -35.2%
EPS (Diluted)
$0.04
-92.5% ▼
5Y CAGR: -35.9%
EBITDA
$333M
-41.2% ▼
5Y CAGR: +0.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $4.0B | $2.1B | $2.0B | $1.8B |
| YoY Growth | +17.9% | +238.0% | -48.4% | -2.0% | -10.1% |
| Cost of Revenue | $530M | $1.9B | $949M | $720M | $0 |
| Gross Profit | $648M | $2.0B | $1.1B | $1.3B | $1.8B |
| Gross Margin | 55.0% | 51.3% | 53.8% | 64.2% | 100.0% |
| R&D Expenses | $131M | $240M | $317M | $337M | $0 |
| SG&A Expenses | $294M | $614M | $558M | $597M | $0 |
| Operating Expenses | $421M | $842M | $764M | $976M | $1.7B |
| Operating Income | $227M | $1.2B | $341M | $315M | $110M |
| Operating Margin | 19.3% | 30.2% | 16.6% | 15.7% | 6.1% |
| Interest Expense | $12M | $9M | $8M | $15M | $0 |
| Income Before Tax | $228M | $1.2B | $334M | $312M | $94M |
| Tax Expense | $24M | $165M | $55M | $40M | $70M |
| Net Income | $205M | $1.0B | $355M | $302M | $24M |
| Net Margin | 17.4% | 25.4% | 17.3% | 15.0% | 1.3% |
| EPS (Diluted) | $0.36 | $1.78 | $0.62 | $0.53 | $0.04 |
| EBITDA | $310M | $1.3B | $441M | $575M | $333M |
| Shares Outstanding | 567M | 569M | 573M | 569M | 600M |